Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Eligible for screening study DCP 001
Completion of Pre-Registration QOLs is required after Pre-Registration (Step 0), prior to registration (Step 1). Please see study documents.
